A prospective phase 1 study testing nivolumab monotherapy in men with HIV on suppressive ART and advanced solid tumors finds measurable immune effects on HIV-specific CD8+ T-cell phenotypes and transcriptional activity. The work links immune checkpoint blockade to shifts in antigen-specific cytotoxic memory cell behavior rather than only generalized checkpoint changes. For the HIV cure field, the trial offers in vivo human evidence on how PD-1 blockade may perturb exhausted T-cell states while patients remain on background antiretroviral therapy. The longitudinal design also highlights the complexity of immune remodeling when HIV and cancer co-exist. The findings reinforce interest in checkpoint blockade as a mechanistic tool in HIV-associated oncology, but they also underline the need to track reservoir-linked endpoints in subsequent studies.
Get the Daily Brief